Revenue segments as reported by the company.

Product revenue

Service and other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Sales, general and administrative

Merger-related expenses

Change in fair value of contingent consideration

Amortization of acquired intangible assets

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pacific Biosciences of California

Pacific Biosciences of California, Inc. engages in the development, manufacture, and marketing of advanced sequencing solutions for genetic analysis. It operates through the following geographical segments: North America, Europe, and Asia Pacific. The company was founded by Stephen Turner and Joseph Vincent Bonventre on July 14, 2000 and is headquartered in Menlo Park, CA.

Earnings data Q1 2024

PacBio reports revenue growth and strong demand for Revio

PacBio's Q1 2023 performance showed revenue growth but faced challenges with gross margin and operating expenses. The company's strengths lie in strong cash position, revenue growth expectations, and successful Revio launch. Opportunities include strong demand for Revio, Onso, and potential projects in China.

PacBio achieves record Q2 revenue, focuses on strategic acquisitions

PacBio's Q2 performance was marked by record revenue and strategic acquisitions. The company is focused on driving growth through Revio momentum, long-read technology integration, and reducing backlog. The Apton acquisition is seen as a strategic move to accelerate product development and drive stronger gross margins.

PacBio achieves record revenue growth, faces macroeconomic challenges ahead

PacBio's Q3 performance reflects strong revenue growth and a focus on expanding its customer base. While facing macroeconomic challenges, the company sees opportunities in the long read sequencing market and plans to drive Revio placements and consumable revenue. Challenges include potential impacts on revenue growth and gross margins.

PacBio reports robust 2023 performance, eyes growth through innovation

PacBio's strong financial performance in 2023 sets the stage for continued growth in 2024, with revenue expected to reach $230-250 million. Strategic priorities focus on driving placements, expanding into clinical markets, and improving gross margins. Challenges with sales cycles and consumable yield are being addressed, while opportunities in new technologies and business models offer avenues for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Pacific Biosciences of California, Inc. engages in the development, manufacture, and marketing of advanced sequencing solutions for genetic analysis. It operates through the following geographical segments: America, Europe, Middle East, and Africa, and Asia Pacific. The company was founded by Stephen Turner and Joseph Vincent Bonventre on July 14, 2000 and is headquartered in Menlo Park, CA.

PacBio's (PACB) revenue growth in the first quarter is likely to have been hampered by an increasing number of customers delaying instrument purchases and softness in consumable shipments.

PacBio (PACB) Preliminary Q1 Revenues Dampened by Purchase Delays

Blade Air Mobility

Roku

Teladoc

At one point Cathie Wood was the hottest money manager on Wall Street. Her family of Ark Invest exchange-traded funds (ETF) grew at a blistering pace, at one point doubling the returns for investors.

The Cathie Wood Stock Shuffle: 4 Names She's Loving, 3 She's Leaving

Announces Plan to Reduce Annualized Operating Expense Run Rate by $50 - $75 Million Q1 2024 Earnings Conference Call Scheduled for May 9, 2024 MENLO PARK, Calif. , April 16, 2024  /PRNewswire/ – PacBio (NASDAQ: PACB) today announced preliminary, unaudited revenue for the quarter ended March 31, 2024.

PacBio Announces Preliminary First Quarter 2024 Revenue and Updates 2024 Revenue Guidance

PacBio's (PACB) strong product demand and top-line growth raise optimism about the stock.

Reasons to Retain PacBio (PACB) Stock in Your Portfolio Now

HiFi Data Generated on the Revio™  System will Support the EU and Estonian Government-Funded Center for Personalized Medicine and Unlock Discoveries Across Cardiology, Mental and Reproductive Health, Drug Response, Cancer Research and Rare Diseases MENLO PARK, Calif. , March 27, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced that the University of Tartu, host of Estonia's National Biobank, has chosen the Revio HiFi sequencing system to sequence 10,000 whole human genomes and unlock new insights from its populational health data.

Estonia National Biobank Selects PacBio to Sequence 10,000 Whole Genomes

MENLO PARK, Calif., March 22, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced that the Compensation Committee of the Company's Board of Directors granted a non-qualified stock option (the "Option") covering an aggregate of 79,600 shares of PacBio common stock and restricted stock units ("RSUs") covering 39,800 shares of PacBio common stock to a recently hired employee under the Pacific Biosciences 2020 Inducement Equity Incentive Plan (the "2020 Inducement Plan"), effective on March 18, 2024.

PacBio Grants Equity Incentive Award to New Employee

PacBio expands product adoption, introducing Revio and Onso, enhancing market and technological reach. Despite 10% growth since 2015, dilution eroded shareholder value; pivot possible with 25% growth through 2029 and improved financing mix. Stand-alone and peer analyses show optimism despite further dilution risks, with brokers forecasting a 178% upside.

Pacific Biosciences' Pivot: From Shareholder Dilution To Expansion And Leadership

Fractyl Health Inc

Inspire Veterinary Partners Inc

Molecular Templates

Outset Medical

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 5 Health Care Stocks Which Could Rescue Your Portfolio In March - Inspire Veterinary (NASDAQ:IVP), Fractyl Health (NASDAQ:GUTS)

PacBio (PACB) announces the PureTarget repeat expansion panel, which is the HiFi long-read sequencing that supports comprehensive analysis of 20 genes associated with neurological diseases.

PacBio's (PACB) New Panel to Aid Its Clinical Research Solution

HiFi Long-Read Sequencing Panel Supports Comprehensive Analysis of 20 Genes Associated With Neurological Disease MENLO PARK, Calif. , March 12, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the PureTarget repeat expansion panel, a new solution designed to enable the comprehensive analysis of 20 genes associated with serious neurological disorders, including challenging-to-sequence genes with tandem repeat expansions.

PacBio Announces PureTarget™ Repeat Expansion Panel, Expanding its Portfolio of End-to-End Clinical Research Solutions

Integra LifeSciences Holdings

Ironwood Pharma

Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In March - Ironwood Pharmaceuticals (NASDAQ:IRWD), Integra Lifesciences (NASDAQ:IART)

MENLO PARK, Calif. , Feb. 26, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be participating in the following upcoming investor conferences: TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024, at 1:30 PM ET in Boston, MA Barclays 26th Annual Global Healthcare Conference on Tuesday, March 12, 2024, at 10:15 AM ET in Miami Beach, FL Live webcasts of the events can be accessed at the company's investors page at investor.pacificbiosciences.com.

PacBio to Present at Upcoming Investor Conferences

PacBio (PACB) witnesses strong revenue growth in the fourth quarter, partly aided by customers' continued product transition to the Revio system.

PacBio (PACB) Q4 Earnings Beat, Adjusted Gross Margin Down

While the top- and bottom-line numbers for Pacific Biosciences (PACB) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Pacific Biosciences (PACB) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

Pacific Biosciences of California, Inc. (PACB) Q4 2023 Earnings Call Transcript

Pacific Biosciences of California (PACB) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.35 per share a year ago.

Pacific Biosciences of California (PACB) Reports Q4 Loss, Tops Revenue Estimates

MENLO PARK, Calif. , Feb. 15, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB) today announced financial results for the quarter and fiscal year ended December 31, 2023.

PacBio Announces Fourth Quarter and Fiscal Year 2023 Financial Results

Archer Aviation

Ginkgo Bioworks Holdings

Pinterest

Palantir Technologies

Rocket Lab USA

Twist Bioscience Corp

You can't say Cathie Wood is afraid to make big bets. The investing guru is more than willing to lay it all on the line for stocks she believes in.

7 Stocks Cathie Wood Is Still Loading Up On in Q1

ATLANTA , Feb. 13, 2024 /PRNewswire/ -- VOLO Events Agency (VOLO), a leading producer of experiential marketing and live events for global brands, has won the best Event Technology award at the BizBash 11th Annual Event Experience Awards. The award recognizes the outstanding use of technology to create an immersive and engaging event experience for PacBio (NASDAQ: PACB) a pioneering leader in the Biotechnology industry.

Experiential Marketing Firm VOLO Events Agency Wins Best Event Technology Award for PacBio Product Launch

PacBio's financials for 2023 show significant growth, with revenue more than doubling in Q4 and a 56% increase in annual revenue compared to the previous year. The company's product innovations, such as the Revio system and Onso sequencer, have driven growth and increased market acceptance of PacBio technology. PacBio's strong cash position, along with its goal of maintaining a compound annual revenue growth rate of 40-50% until 2026, makes it an attractive investment in the biotech sector.

Pacific Biosciences: Strong Cash And Doubling Revenue Signal Investment Growth

PacBio's (PACB) new library preparation kits are likely to boost Revio's long-read sequencing systems by reducing cost and workflow time.

PacBio's (PACB) New Kits to Boost Its Revio Sequencing System

New Library Preparation Solutions Offer Never Before Achieved Scale for the Revio™  Sequencing System MENLO PARK, Calif. , Feb. 5, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced two new high throughput library preparation kits and workflows optimized for its Revio sequencing system.

PacBio Announces HiFi Prep Kit 96 and HiFi Plex Prep Kit 96 for Long-Read Sequencing Applications at Scale

MENLO PARK, Calif. , Jan. 25, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its fourth quarter 2023 financial results on Thursday, February 15, 2024, at 5:00 pm Eastern Time.

PacBio to Report Fourth Quarter 2023 Financial Results on February 15, 2024

PacBio's (PACB) new offering, PanDNA kit, is likely to help researchers effectively extract DNA optimized for HiFi sequencing. This versatile Nanobind kit is expected to be available in February 2024.

PacBio's (PACB) New PanDNA Kit Ready to Boost DNA Extraction

Existing HT CBB Kit Enables High-Throughput Extraction of HMW DNA Tailored for HiFi With an Updated Workflow for Animal Blood and Bacteria MENLO PARK, Calif. , Jan. 15, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced PanDNA, a versatile Nanobind DNA extraction kit.

News for Pacific Biosciences of California Stock (PACB)